Two-Year Study of the Safety and Efficacy of the Second-Generation Tissue Engineered Vascular Grafts

NCT04467671 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

24

Enrollment

OTHER

Sponsor class

Conditions

HLH - Hypoplastic Left Heart Syndrome
DORV
DILV - Double Inlet Left Ventricle
Mitral Atresia
Tricuspid Atresia
Unbalanced AV Canal
Single-ventricle
Heart Defects, Congenital
Cardiovascular Abnormalities
Cardiovascular Diseases
Heart Diseases

Interventions

COMBINATION_PRODUCT: Tissue Engineered Vascular Grafts

Sponsor

Nationwide Children's Hospital

Collaborators

[object Object]
[object Object]
[object Object]